Kornimate/medical-research-clean huggingface dataset:
lamictal in the treatment of post-herpetic neuralgia

Conditions: Neuralgia, Postherpetic

Summary: to assess the efficacy of lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.


Eligibility criteria:
inclusion criteria: * all patients will be over the age of 18, * need to have a diagnosis of post-herpetic neuralgia, * minimum of 4 on the likert pain scale, * if currently taking tca and/or gabapentin, need to have been on stable dose for minimum of 4 weeks exclusion criteria: * currently on any antiepileptic drugs (aed), except for gabapentin. * currently taking opioid or unwilling to washout prior to the study, * pregnant and lactating, * have active severe systemic disease, * history of stevens-johnson syndrome or ten, * clinically significant abnormal lab values, * known drug allergy to lamictal, * patients on fibrates (tricor and lopid), * history of major psychiatric disturbance and substance abuse. * valproate due to increase chances of severe rash, * lidocaine patch, * use of hormonal contraceptives (birth control pills, patch, ring, injection)

Keywords: inclusion criteria:minimum of 4 on the likert pain scale.if currently taking tca and/or gabapentin, need to have been on stable dose for minimum of 4 weeks. exclusion criteria: currently on any antiepilepic drugs (aed), except for gabapentin. currently taking opioid or unwilling to washout prior to the study, pregnant and lactating, have active severe systemic disease, history of stevens-johnson syndrome or ten,
with love, grandma ("con cariño, abuelita") pilot study

Conditions: Cancer, Breast; Cancer, Uterus; Cancer, Ovary; Obesity; Activity, Motor; Diet, Healthy

Summary: the purpose of this study is to assess the feasibility, acceptability, and preliminary effects of a digital (web and mobile-phone-based) program to improve lifestyle behaviors (physical activity, dietary intake) among hispanic female cancer survivors and adult daughters.


Eligibility criteria:
cancer survivor inclusion criteria: * grandmother * self-identifies as hispanic * diagnosis of breast cancer (stages i-iii), endometrial or ovarian cancer (stages i-ii) * completed active treatment (i.e., surgery, chemotherapy, and/or radiation) * body mass index (bmi) ≥ 25 (overweight range) * engages in \<150 minutes/week of moderate physical activity * english or spanish speaking * owns a mobile device with internet access (e.g., smartphone, tablet) * lives in south florida daughter of cancer survivor inclusion criteria: * adult daughter of the identified cancer survivor (21 years of age or older) * has at least 1 living child ages ≤16 years old * body mass index (bmi) ≥ 25 (overweight range) or engages in \<150 minutes/week of moderate physical activity * english or spanish speaking * owns a mobile device with internet access (e.g., smartphone, tablet) * lives in south florida daughter of cancer survivor exclusion criteria: * has been diagnosed with distant metastatic cancer * has not completed active treatment (i.e., surgery, chemotherapy, and/or radiation) * has uncontrolled schizophrenia or bipolar disorder * has a preexisting medical condition that precludes unsupervised physical activity (e.g., severe orthopedic conditions,wheelchair bound). cancer survivor exclusion criteria: * has uncontrolled schizophrenia or bipolar disorder * has a preexisting medical condition that precludes unsupervised physical activity (e.g., severe orthopedic conditions, wheelchair bound)

Keywords: hispanic family digital health cancer survivorship physical activity nutrition
swimming adapted, therapeutic exercise and health education in the treatment of chronic neck pain

Conditions: Chronic Neck Pain

Summary: chronic neck pain (cnp) is defined as pain or intense discomfort in the lateral or back of the neck with an establishment and/or persistence period of over 12 weeks. the socio-economic system is seriously affected by chronic neck pain due to direct and indirect costs on the health system physical exercise is used to improve physical function and reduce the symptoms of pain and stiffness due to chronic neck pain. it has been demonstrated that therapeutic exercise in water is effective to improve functional capacity and symptoms in patients with chronic neck pain. in adition, health education and posture is an important component of the overall treatment of neck pain. interventions that integrate physical activity, adapted swimming and health education as an intervention for chronic neck pain sufferers have not been found. furthermore the aim of this study is to analyse the effect of a physiothperapy treatment that combine adapted swimming, therapeutic exercise and health education in patients with chronic neck pain. hypothesis: the present intervention will be an effective tool to treat patients suffering chronic neck pain. methods: chronic neck pain patients from a community-based centre will be recruite participate in this prospective study. intervention: 60 min session: 30 min of land exercise dedicated to improve mobility, motor control, resistance and strengthening of the neck muscles, 30 min of adapted swimming with aerobic exercise keeping neutral neck position by using a snorkel. health education will be provided by the physiotherapist before and during the sessions using a decalogue on chronic neck pain and constant repetition of brief advice. study outcomes: disability (neck disability index), physical and mental health state and quality of life of patients (sf-12 and euroqol 5d respectively). differences between baseline data and that at the 8-week follow-up were calculated for all outcome variables. statistical analysis: descriptive statistics. analysis of the normal distribution of the variables using the ks-test. comparison of variables pre - post intervencición: t-student for parametric variables and wilcoxon test for non parametric variables. data will be analysed descriptively and for statistical significance using statistical package for the social sciences (spss) (version 17.0 for windows, illinois, usa).


Eligibility criteria:
inclusion criteria: * suffers neck pain for more than 12 weeks. * delivery of informed consent. exclusion criteria: * neck pain due to an identifiable cause. * surgery on the spine in the 12 month * traffic accident in the last 3 months * cervical radiculopathy * pregnancy. * patients who suffered a condition that could alter the effects of treatment * people who could not swim and/or present treatment difficulty.

Keywords: neck pain physiotherapy adapted swimming therapeutic exercises health education
study of biological effect of tarceva (osi-774) for patients stricken by ent epidermoid carcinoma

Conditions: Head and Neck Neoplasms

Summary: the purpose of this study is to evaluate the biological effect of tarceva (osi-774) from an inhibition of egf tumor receptor tyrosine kinase activity's point of view, for patients who are carriers of head and neck epidermoid carcinoma.

patients will receive tarceva in continuous between 18 and 28 days after pan-endoscopy exam until surgery

Eligibility criteria:
inclusion criteria: * neck and head epidermoid carcinoma histologically proved. patient with an ent epidermoid tumor can be included in the study if this relapse is located in an area not irradiated yet. * at least tumor classified t2nxm0 * patient who can be picked up in a first surgery with a curative purpose or who must have a necessity's surgery (cervical curettage for voluminous adenopathies before radiotherapy) * patient without clinical or radiological sign of metastatic disease * good general status (oms ≤ 2) * patient able to ingest food. * age ≥ 18 years * well-informed written consent, signed by the patient. * patient with sickness benefit exclusion criteria: * patient with relapse ever treated by radiotherapy * other prospective study's participation * recent and massive digestive haemorrhage * medical contra-indication like main general status alteration, uncontrolled serious infectious disease, main uncontrolled metabolic anomaly ongoing. * pre-existent pulmonary pathology (bpco, pleurisy, lymphangitis, interstitial syndrome) * severe cardiac pathology (stage 3 or 4 cardiac insufficiency, unstable angina pectoris, uncontrolled arrhythmia, myocardium's infarction antecedent during the year that precede the inclusion. * ophthalmic pathology antecedent concerning the ocular surface or lens-carrier * concomitant administration, by local or general tract, of drug responsible for ocular drought or which could delay the epithelial cicatrization * less than 1000 polynuclear neutrophil leucocytes or less than 75000 blood-platelets at inclusion * bilirubin at higher concentration than one point five times the normal * renal insufficiency (glomerular filtration flow ≤ 40 ml/min)calculated in accordance with cockroft's formula * tacking of beta blockers, amiodarone, nsaids, bleomycin, just before or during the study * pregnant or nursing women * patient under guardianship or trusteeship.

Keywords: head and neck neoplasms tarceva ent
effects of periodic fasting versus daily energy restriction on metabolic health

Conditions: Insulin Resistance

Summary: the aim of this study is to examine whether periodic fasting improves markers of diabetes risk and cardiovascular health, and will compare this to the effects observed with daily dieting by energy restriction, and also with no change in energy intake. it is hypothesized that periodic fasting, with or without weight loss, will be as effective as daily energy restriction to improve markers of metabolic health and energy metabolism.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 25 and 42 kg/m2 * weight stable (\<5% fluctuation in body weight for the 6 months prior to study entry) exclusion criteria: * history of cardiovascular disease, diabetes, major psychiatric disorders, and eating disorders * use of prescribed or non-prescribed medications with may affect energy metabolism, gastrointestinal function, body weight, or appetite * recent weight changes in 3 months prior to study entry * uncontrolled asthma, current fever, upper respiratory infections * individuals who regularly perform high intensity exercise (\>2 sessions per week) * pregnancy, lactation (breast feeding), women who are planning to become pregnant * current intake of \>140g of alcohol per week * current smoker of cigarettes/cigars/marijuana * current intake of any illicit substance * experience claustrophobia in confined spaces * has donated blood within the past 3 months * unable to comprehend the study protocol * experiences migraines
pre-operative magnetic resonance imaging (mri) in young breast cancer patients

Conditions: Breast Cancer; Magnetic Resonance Imaging; Preoperative MRI

Summary: young women with breast cancer have an increased breast tissue density and conventional imaging tests such as mammography and breast ultrasound are less sensitive and specific for detecting breast cancer than in older breast cancer patients. breast mri is an emerging tool that has been proven to improve the ability to identify breast cancers by determining the extent of disease and also detect multifocal, multicentric and bilateral breast cancers. to date, the role of pre-operative breast mri is not clearly defined. the investigators are proposing a study to evaluate the impact of preoperative breast mri on surgical decision-making in breast cancer patients \<= 50 years. this may lead to improved characterization of breast cancers in these younger patients that may ultimately result in lower local recurrence rates in the future. the additional information attained through the breast mri may also guide the use of radiation, chemotherapy and/or hormonal therapy in these patients.

inclusion criteria: * female aged ≤ 50 * histologically proven invasive breast cancer exclusion criteria: * is not considered a surgical candidate * has had prior breast cancer surgery or an excisional biopsy of the newly diagnosed lesion * has a contraindication to undergoing breast mri * has inflammatory breast cancer according to the standard clinical definition * has locally advanced breast cancer according to the standard clinical definition * patient is pregnant * has a psychiatric or addictive disorder that would preclude obtaining informed consent or adherence to the protocol

Eligibility criteria:
inclusion criteria: * female aged \<= 50 years * histological proof of invasive breast cancer via fine needle aspiration or core needle biopsy * premenopausal exclusion criteria: * patient not considered an appropriate surgical candidate; i.e., patient is not well enough to have breast cancer surgery * patient has had prior breast cancer surgery or an excisional biopsy of the newly diagnosed cancer * patient has a contraindication to undergoing breast mri (i.e., pacemaker, neurodefibrillator, metallic foreign bodies, etc.) * patient has inflammatory breast cancer according to the standard clinical definition. this is a type of breast cancer in which there is evidence of erythema and/or edema. the skin of the breast may also have changes of peau d'orange. * patient has locally advanced breast cancer according to the standard clinical definition. * patient is pregnant * patient has a psychiatric or addictive disorder that would preclude them from obtaining informed consent.

Keywords: breast cancer magnetic resonance imaging preoperative mri
economic evaluation of vancomycin therapeutic drug monitoring methods

Conditions: Infection, Bacterial

Summary: vancomycin is a widely used antibiotic in the treatment of complicated gram positive infections. approaches to vancomycin therapeutic drug monitioring (tdm) vary. this clinical trial aimed to compare the pharmacoeconomic outcomes between various vancomyicn tdm approaches. research questions: which vancomycin therapeutic drug monitoring (tdm) approach is associated with superior economic outcomes? -objectives: in this proposed multicenter randomized controlled trial (rct), we aim to compare the pharmacoeconomic outcomes of various vancomycin tdm approaches.


Eligibility criteria:
inclusion criteria: * adults at least 18 yrs who are hospitalized and initiated on iv vancomycin exclusion criteria: * renal instability * immunosuppression; * vancomycin allergy; * history of recurrent peritonitis * administration of \< 4 doses of vancomycin * pregnancy; * hemoglobin \< 8 g/dl.
a single-blind placebo run-in study of venlafaxine for activity-limiting osteoarthritis pain

Conditions: Osteoarthritis; Pain

Summary: this will be a single-blind, placebo-run-in trial. subjects will be informed that they may receive venlafaxine or placebo during the course of the trial. all subjects will, in fact, receive placebo for the first two weeks. all subjects will then be placed on 150-225 mg per day of venlafaxine. primary outcome assessment will compare pain intensity at 2 weeks (after placebo) to that at 12 weeks (after 10 weeks of venlafaxine treatment). study hypothesis: in subjects who continue to have activity-limiting osteoarthritis pain after treatment with acetaminophen or non-steroidal anti-inflammatory agents, 150-225 mg venlafaxine per day over 10 weeks will provide significant additional pain relief over that achieved with placebo (more than 30% reduction after venlafaxine treatment).


Eligibility criteria:
inclusion criteria: * age 50 - 80 years * physician diagnosis of oa in hip, knee or spine * significant activity limitation due to pain for at least one month on the western ontario and mcmasters university osteoarthritis index (womac) and average pain more than 5/10 on brief pain inventory despite adequate treatment with acetaminophen or nsaids (this will identify an oa group with significant psychological distress and a desire for treatment). * depression status is not restricted, but will be monitored with prime-md interview and the scl-20. we anticipate depressive symptoms will be common in this population due to the above requirement for activity limitation. exclusion criteria: * cannot read and write english * significant cognitive impairment * history of psychosis or mania * current suicidal ideation * current substance abuse or dependence * current use of opioids or any antidepressant medication * use of investigational drug within the past month

Keywords: osteoarthritis pain activity limitation antidepressant depression single-blind
real world evidence in china: faricimab use in diabetic macular edema, retinal vein occlusion, and neovascular age-related macular degeneration (the farseeing study)

Conditions: Diabetic Macular Edema; Neovascular Age-related Macular Degeneration; Retinal Vein Occlusion

Summary: the farseeing study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in china. it is a primary data collection, non-interventional, prospective and retrospective, multi-center study designed to collect real-world, long-term data to gain clinical evidence on faricimab, by observing cohorts of patients with neovascular age-related macular degeneration (namd), diabetic macular edema (dme), and retinal vein occlusion (rvo) who are receiving treatment with faricimab.


Eligibility criteria:
inclusion criteria: 1. have signed the informed consent 2. female and male chinese patients, who had been diagnosed with namd, dme, or rvo by cfp, oct, ffa, icga, or octa 3. ≥50 years old for patients with namd, ≥18 years old both for patients with dme and rvo, at the time of signing informed consent (or the first administration of faricimab, whichever occurs first) 4. patients for whom the decision to receive treatment with faricimab is made prior to and independent from study participation 5. patients have received at least one faricimab treatment (the first dose) in the study eye exclusion criteria: 1. patients not receiving treatment for namd/dme/rvo with faricimab according to the standard of care and in line with the current summary of product characteristics (spc) / labeling in china 2. active ocular inflammation or suspected / active ocular infection in either eye 3. received any other anti-vegf treatment after faricimab 4. received any steroid treatment within 6 months (180 days) before the first faricimab treatment in the study eye 5. any participation in any other clinical trials currently 6. patients could not provide the clinical data (visual acuity and oct images) within 2 weeks (14 days) before receiving the initial faricimab injection
autologous bone marrow-derived cd34+, cd133+, and cd271+ stem cell transplantation for retinitis pigmentosa

Conditions: Retinitis Pigmentosa

Summary: a single arm, single center trial to evaluate the safety and efficacy of autologous purified populations of bone-marrow derived stem cells in patients with retinitis pigmentosa (bm-scs) through a 48 month follow up period.

retinitis pigmentosa (rp) is an inherited disorder of the photoreceptor cells in the retina. patients may lose vision since they were young or later in life. currently, there are more than 60 genes identified as the cause of this condition, one of which, rpe65, has been studied in several gene therapy trials for leber congenital amaurosis with promising results. another treatment approach for rp is stem cell therapy. studies in animal models of rp have shown that subretinal injection of bone marrow-derived mesenchymal stem cells may delay degenerative changes of photoreceptor cells. this is a single arm, single center trial to assess the safety and efficacy of purified adult autologous bone marrow derived cd34+, cd133+, and cd271+ stem cells through a 48 month follow-up period. the combination of these three cell types was based on their diverse potentialities to differentiate into specific functional cell types to regenerate damaged retinal tissue, and the availability of clinical-grade purification system (clinimacs) and microbeads to purify the target cell populations in clinically-approved methods.

Eligibility criteria:
inclusion criteria: * retinitis pigmentosa patients diagnosed by ophthalmologists * visual acuity (measured with etdrs) less than or equal to 20/70 and visual field below 30° central in both eyes. * best corrected visual acuity less than 6/120 by snellen visual acuity chart exclusion criteria: * other eye conditions that could mask the interpretation of the results * unable to return for follow up * underlying diseases including asthma, heart failure, myocardial infarction, liver failure, renal failure * pregnant and lactating women
impact of nitrate ingestion on protein synthesis

Conditions: Muscle Protein Synthesis

Summary: a diet rich in leafy green vegetables has been shown to reduce the risk of developing chronic metabolic disease. the health benefits from these particular vegetables may be attributed to their high nitrate content. recent work suggests that dietary nitrate triggers endogenous nitric oxide release, thereby stimulating vasodilation and improving muscle perfusion in an insulin-independent manner. we hypothesize that in an insulin-resistant state, nitrate co-ingestion will increase muscle perfusion, thereby improving post-prandial delivery of nutrients to skeletal muscle tissue. specifically, a more efficient delivery of food derived amino acids will stimulate post-prandial muscle protein synthesis and, as such, compensate for a blunted muscle protein synthetic response to food intake in the elderly. this proposal will investigate the efficacy of nitrate co-ingestion as a means to augment muscle protein synthesis in elderly, type 2 diabetes patients and may lead to a novel therapy in the clinical care of type 2 diabetes patients.


Eligibility criteria:
inclusion criteria: * male * aged between 70-85 years * bmi \< 30 kg/m2 * non insulin-dependent diabetes mellitus type 2 patients (t2dm) ( \>1 y since diagnoses) exclusion criteria: * smoking * hypertension (according to who criteria)\[29\] and/or cardiovascular disease treated with medication containing nitrates and/or having vasodilatory effects * use of medication, except for oral blood glucose lowering medication * use of insulin * all co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis). * hba1c \> 10.0% (86 mmol/mol) * donated blood in last 3 months * diagnosed impaired renal or liver function * myocardial infarction within the last 3 years * gastric acid inhibitors * use of anti-coagulants

Keywords: type ii diabetes protein synthesis nitrate elderly